Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time
- 10 June 2012
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (17) , 2165
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid CancerJournal of Clinical Oncology, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor GroupJournal of Clinical Oncology, 2006
- Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2005